Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis
European Journal of Haematology · 2025-03 · 114 (3) · 443-447
DOI: 10.1111/ejh.14348 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 17.11.2024. Verfasst von Margaret Stalker und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Antibodies, Bispecific. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Teclistamab has demonstrated deep responses in patients with multiple myeloma in the MajesTEC‐1 study. However, the safety and efficacy of teclistamab in patients with AL amyloidosis are unknown.
Methods
We retrospectively analyzed patients with biopsy‐proven relapsed/refractory AL amyloidosis who were treated with teclistamab from December 2022 to February 2024 at the University of Pennsylvania. The data cutoff was 2/29/24. Adverse events (AE) were extracted from the electronic medical record. Patients were assessed for hematologic and organ response per consensus guidelines.
Results
Eight patients were included in this case series: median age 63 (range 59–67), 75% female, 88% White. All eight patients achieved at least very good partial response (VGPR) and had normalization of free light chains (FLC), and six (75%) patients achieved undetectable FLC levels. Of the six patients with immunofixation completed, all six (100%) achieved hematologic complete response (hCR). The median time to hematologic VGPR and hCR was 13 days (range 12–18 days) and 88 days (range 32–150 days), respectively. The median duration of follow‐up was 8.5 months (range 1–14 months). Of the five patients with cardiac involvement, four (80%) achieved a cardiac response. Of the seven patients with renal involvement, two patients already achieved renal response prior to teclistamab, and of the remaining five, three (60%) achieved renal response. Six patients (75%) developed low‐grade cytokine release syndrome (CRS). No patients developed ICANS. Neutropenia and AKI both occurred in 25% of patients, respectively.
Conclusions
In this series of patients, teclistamab showed outstanding depth of response and was well‐tolerated. Teclistamab shows promise in treating patients with relapsed AL amyloidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Margaret Stalker, Dan T Vogl, Mia Djulbegovic
Zitieren
APA
Stalker, M., Garfall, A., Cohen, A., Vogl, D. T., Djulbegovic, M., Susanibar-Adaniya, S., Stadtmauer, E., Megherea, O., & Waxman, A. J. (2025). Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis. European Journal of Haematology, 114(3), 443-447. https://doi.org/10.1111/ejh.14348
Vancouver
Stalker M, Garfall A, Cohen A, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, et al. Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis. European Journal of Haematology. 2025;114(3):443-447. doi:10.1111/ejh.14348
BibTeX
@article{Stalker2025,
author = {Stalker, Margaret and Garfall, Alfred and Cohen, Adam and Vogl, Dan T and Djulbegovic, Mia and Susanibar-Adaniya, Sandra and Stadtmauer, Edward and Megherea, Oxana and Waxman, Adam J},
title = {Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis},
journal = {European Journal of Haematology},
year = {2025},
volume = {114},
number = {3},
pages = {443--447},
doi = {10.1111/ejh.14348}
}
EUVIMED